An experimental drug designed by AI appears to reverse biological aging markers in early trials, with independent aging clocks suggesting treated patients were up to six years biologically younger than those on placebo.
Rentosertib, developed by Insilico Medicine using artificial intelligence, showed promising results in a Nature Biotechnology study of 42 patients. Six independent aging clocks—different computational models that measure biological age—predicted the drug reversed aging markers in treated participants.
The trial measured biological aging rather than chronological age. Participants receiving rentosertib displayed aging markers consistent with someone six years younger than the placebo group, according to the aging clock assessments.
Insilico Medicine used AI to identify drug candidates by analyzing biological data and genetic information. The company screened thousands of potential compounds before selecting rentosertib for testing. This represents one of the first major pharmaceutical applications of AI drug discovery reaching human trials with measurable biological outcomes.
However, significant limitations remain. The trial involved only 42 patients—a small sample for drawing broad conclusions. Participants were not healthy individuals; the drug was tested on a specific patient population. Longer-term studies are needed to determine whether biological age reversal translates to improved health outcomes or extended lifespan.
The study also did not assess safety data comprehensively or track participants over extended periods. Additional trials must evaluate whether the effects persist and whether the drug produces adverse effects in larger populations.
Drug development typically requires multiple trial phases before regulatory approval. Moving from a 42-person early trial to widespread use involves years of additional testing. Aging clock models themselves remain an evolving field, with scientists debating which measurements most accurately predict biological age and health outcomes.
The results signal progress in AI-assisted drug discovery and aging research, but investors and patients should interpret early-stage findings cautiously. Real-world applications remain years away pending further clinical validation.
Google's Astra AI demonstrating computer use capabilities through Blender suggests AI tool use could become the industry's next major growth driver, following chatbots, reasoning models, and agentic coding.
ChatGPT has recovered its dominant position in AI chatbot web traffic, capturing 55.5 percent of visits according to Similarweb. The rebound comes as Gemini's momentum falters, though both competitors have significantly eroded ChatGPT's year-over-year lead from 73.3 percent.
Companies prioritizing trustworthy AI practices see stronger returns on investment, according to new SAS research. However, widespread skepticism undermines adoption: 97% of users override AI recommendations regularly.
ChatGPT has decimated Kenya's essay-writing business model that served foreign students. The AI tool has rendered an entire Nairobi-based industry obsolete.